Summit Therapeutics PLC (SMMT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Summit Therapeutics PLC stock (SMMT) is currently trading at $17.94. Summit Therapeutics PLC PS ratio (Price-to-Sales) is 753.90. Analyst consensus price target for SMMT is $29.53. WallStSmart rates SMMT as Sell.
- SMMT PE ratio analysis and historical PE chart
- SMMT PS ratio (Price-to-Sales) history and trend
- SMMT intrinsic value — DCF, Graham Number, EPV models
- SMMT stock price prediction 2025 2026 2027 2028 2029 2030
- SMMT fair value vs current price
- SMMT insider transactions and insider buying
- Is SMMT undervalued or overvalued?
- Summit Therapeutics PLC financial analysis — revenue, earnings, cash flow
- SMMT Piotroski F-Score and Altman Z-Score
- SMMT analyst price target and Smart Rating
Summit Therapeutics
📊 No data available
Try selecting a different time range
Smart Analysis
Summit Therapeutics PLC (SMMT) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Summit Therapeutics PLC (SMMT) Key Strengths (1)
Large-cap company with substantial market presence
Supporting Valuation Data
Summit Therapeutics PLC (SMMT) Areas to Watch (5)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 753.9x annual revenue
Very expensive at 18.3x book value
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Summit Therapeutics PLC (SMMT) Detailed Analysis Report
Overall Assessment
This company scores 15/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Market Cap.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (753.90), Price/Book (18.25) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -206.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -206.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SMMT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SMMT's Price-to-Sales ratio of 753.90x trades at a deep discount to its historical average of 2378.58x (36th percentile). The current valuation is 92% below its historical high of 9180.08x set in May 2024, and 4414% above its historical low of 16.7x in Jun 2019.
WallStSmart Analysis Synopsis
Data-driven financial summary for Summit Therapeutics PLC (SMMT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Summit Therapeutics PLC operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -100M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Summit Therapeutics PLC.
Bottom Line
Summit Therapeutics PLC offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(13 last 3 months)
| Insider | Type | Shares |
|---|---|---|
ANAND, BHASKAR Chief Accounting Officer | Buy | +30,000 |
Data sourced from SEC Form 4 filings
Last updated: 2:34:39 PM
About Summit Therapeutics PLC(SMMT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.